Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Olanzapine.

Literature DB >> 9619205

Olanzapine.

Abstract

Olanzapine is a newly introduced atypical neuroleptic, with a broad receptor profile similar to that of clozapine. It is as effective as haloperidol against the positive symptoms of schizophrenia, and more effective against negative symptoms, with significantly fewer extrapyramidal side-effects. Side-effects include somnolence and weight gain. It may show efficacy in treatment-resistant schizophrenia.

Entities: Chemical Disease

Mesh：

Substances：

Year: 1997 PMID： 9619205

Source DB: PubMed Journal: Br J Hosp Med ISSN： 0007-1064

Keyword Cloud
Cited

12 in total

Review 1. Management of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients.

Authors: Rudolph M Navari
Journal: Paediatr Drugs Date: 2017-06 Impact factor: 3.022

2. Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting.

Authors: Rudolph M Navari; Rui Qin; Kathryn J Ruddy; Heshan Liu; Steven F Powell; Madhuri Bajaj; Leah Dietrich; David Biggs; Jacqueline M Lafky; Charles L Loprinzi
Journal: N Engl J Med Date: 2016-07-14 Impact factor: 91.245

3. A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study.

Authors: Rudolph M Navari; Lawrence H Einhorn; Patrick J Loehrer; Steven D Passik; Jake Vinson; John McClean; Naveed Chowhan; Nasser H Hanna; Cynthia S Johnson
Journal: Support Care Cancer Date: 2007-03-21 Impact factor: 3.603

4. A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study.

Authors: Rudolph M Navari; Lawrence H Einhorn; Steven D Passik; Patrick J Loehrer; Cynthia Johnson; M L Mayer; J McClean; Jake Vinson; W Pletcher
Journal: Support Care Cancer Date: 2005-02-08 Impact factor: 3.603

5. Treatment of Central Vertigo With Low Dose Olanzapine: Report of Two Cases.

Authors: Connie Jiang; Anusha Lekshminarayanan; Ihsan Balkaya; Alal Uddin; Sheital Bavishi; Eric Altschuler
Journal: Cureus Date: 2022-02-27

6. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.

Authors: Rudolph M Navari; Cindy K Nagy; Sarah E Gray
Journal: Support Care Cancer Date: 2013-01-12 Impact factor: 3.603

Olanzapine.

Review 1. Management of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients.

2. Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting.

3. A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study.

4. A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study.

5. Treatment of Central Vertigo With Low Dose Olanzapine: Report of Two Cases.

6. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.

7. Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents.

8. Treatment of cancer-related anorexia with olanzapine and megestrol acetate: a randomized trial.

Review 9. Management of chemotherapy-induced nausea and vomiting : focus on newer agents and new uses for older agents.

10. Olanzapine as antiemetic drug in oncology: a retrospective study in non-responders to standard antiemetic therapy.